聯系電話:512-67626747 聯系郵箱:eegene215@qq.com
合作廠商登彔/蘇州翊準基因科技有限公司

2009.Clin Cancer Res 2009 Jul. 15.4508-13_Kras. Cetuximab.

發布時間:2016-10-28 ??? 閱讀數:

 PURPOSE:

Previously we developed membrane-arrays as a promising tool to detect circulating tumor cells (CTC) with KRAS oncogene in patients with malignancies. This study was conducted to determinate the predictive values of CTCs with KARS mutation by membrane-arrays for metastatic colorectal cancer patients treated with cetuximab plus chemotherapy.
EXPERIMENTAL DESIGN:
Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled. KRAS mutation status in the peripheral blood of these patients was analyzed using membrane-arrays, and KRAS mutation status in tumors was analyzed by DNA sequencing.
RESULTS:
Among 76 metastatic colorectal cancer patients, KRAS mutations in tumors and in peripheral blood were identified in 33 (43.4%) and 30 (39.5%) patients, respectively. The detection sensitivity, specificity, and accuracy of membrane-arrays for CTCs with KRAS oncogene were 84.4%, 95.3%, and 90.8%, respectively, and indeed a highly significant correlation to KRAS mutations in tumors (P < 0.0001) was observed. Forty-five (59.2%) patients responded to cetuximab plus chemotherapy, and 41 and 40 were wild-type KRAS in tumors and peripheral blood, respectively (both P < 0.0001). Patients with tumors that harbor wild-type KRAS are more likely to have a better progression-free survival and overall survival when treated with cetuximab plus chemotherapy (P < 0.0001). Likewise, patients with CTCs of wild-type KRAS in peripheral blood express a better progression-free survival and overall survival when treated with cetuximab plus chemotherapy (P < 0.0001).
CONCLUSIONS:
These findings provide evidence that detection of KRAS mutational status in CTCs, by gene expression array, has potential for clinical application in selecting metastatic colorectal cancer patients most likely to benefit from cetuximab therapy.

上一篇: 2008.技術平臺專書-Methods of Cancer Diagnosis, Therapy
下一篇: 2009.Fooyin J Health Sci 2009 Nov.1(2)72-80_automatic chipb

  • 蘇州翊準基因科技
    中國江蘇省蘇州市工業園區新平街388號B幢B-203(騰飛創新園塔樓B-203)
    電話:86-512-67626747
    傳真:86-512-67626747
    QQ:2957745965

Copyright © 2016 蘇州翊準基因科技有限公司 版權所有 蘇ICP備17013352號

伊人影院蕉久影院在线_伊人影院蕉久影院在线99_伊人影院蕉久草院在线